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Abstract
Background: The primary objective of this prospective study was to measure the change from
baseline in visual function – Best-Corrected Visual Acuity (BCVA) via the Early Treatment Diabetic
Retinopathy Study (ETDRS) chart, contrast sensitivity, central 10 degree visual fields and retinal
imaging (angiograms and photographs) at 6 months in subjects with atrophic (dry) age-related
macular degeneration treated with a targeted nutritional supplement.
Methods: 37 mixed gender patients with a mean age of 76.3 +/- 7.8 years were enrolled at 5
independent study sites and received standard of care with a novel formulation of a nutritional
supplement. Results were compared to a placebo cohort constructed from the literature that was
matched for inclusion and exclusion criteria. A paired t-test was used to test a null hypothesis and
a two-sided alpha level of 0.05 was used to determine statistical significance.
Results: 76.7% of subjects receiving the nutritional supplement demonstrated stabilization or
improvement of BCVA at 6 months. Subjects gained an average of 0.0541 logMAR or one-half of a
line of visual acuity (VA) over the 6-month period. There was a statistically significant improvement
in VA from baseline with P = .045. The results provide strong evidence that the treatment being
studied produces an improvement in VA.
Conclusion: Treatment with this unique nutritional supplement increased VA above the expected
baseline decrease in the majority of patients in this population with dry macular degeneration. The
results of the TOZAL study agree with the LAST and CARMIS studies and are predictive for
positive visual acuity outcomes in the AREDS II trial. However, patients will likely require
supplementation for longer than 6 months to effect changes in additional visual parameters.
Background
Age-related Macular Degeneration (AMD) is a progressive
disorder associated with central vision loss and is the lead-
ing cause of visual impairment and blindness in people
over the age of 60. More than 15 million Americans over
the age of 60 have AMD with an additional 50 million
Americans at risk for developing the disorder [1]. Dry,
atrophic, or non-exudative, AMD is the most common
form and is characterized by progressive devitalization of
retinal pigment epithelium (RPE) and the formation of
fatty deposits under the RPE known as soft drusen [1].
Although the underlying cause of AMD is unknown, risk
factors have been defined and include age greater than 50,
Caucasian race, nutrition, smoking, atherosclerotic vascu-
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lar disease, genetics, and sunlight exposure [1-4]. At this
time, there is no known cure for AMD. Patients not receiv-
ing treatment have demonstrated a loss of VA at 6 months
of at least 0.8 lines and up to 1.5 lines [5-7].
Multiple studies have suggested that manipulation of
nutritional factors can play a significant role in slowing
the onset or limiting the effects of AMD [8-13]. In 1996,
Richer et al found that a broad-spectrum antioxidant and
mineral supplement was effective in delaying AMD-
related vision loss, but was unable to reverse existing
vision loss [14,15]. The Age-Related Eye Disease Study
(AREDS), sponsored by the National Eye Institute, dem-
onstrated that high levels of antioxidants and zinc were
able to reduced the risk of development of advanced AMD
by approximately 25% [16]. In 2004, the Lutein Antioxi-
dant Supplementation Trial (LAST) demonstrated that
nutritional supplementation with lutein or lutein together
with antioxidants, vitamins, and minerals improved vis-
ual function and symptoms in patients with atrophic age-
related macular degeneration [13].
Nutritional supplements have become the first line of
defense for clinicians in battling dry AMD. Vitamin and
mineral formulations are a valid therapeutic tool and are
many orders of magnitude less toxic than aspirin and
acetaminophen [17].
The Taurine, Omega-3 Fatty Acids, Zinc, Antioxidant,
Lutein (TOZAL) study sought to identify the potential
benefits of a novel supplement designed to limit the risk
of AMD and progressive vision loss while also reducing or
eliminating the risk of adverse events.
Methods
This study was approved by an independent ethics com-
mittee and an independent review board and was con-
ducted at five independent clinical sites. The study was
conducted from 2004 through 2005.
Study Design
This prospective, double-blind, 6-month trial enrolled 73
subjects with at least 1 eye diagnosed with dry AMD. There
were 5 independent study sites: site 1 enrolled 19 patients,
site 2 enrolled 15 patients, site 3 enrolled 13 patients, site
4 enrolled 12 patients, and site 5 enrolled 14 patients.
Patients were randomly assigned 1 of 2 treatment arms: 1)
microcurrent stimulation (MCS) treatment and nutri-
tional supplement (n = 36), and 2) sham MCS and nutri-
tional supplement (n = 37).
In 1998, Allen et al reported that patients with dry AMD
treated with a combination of nutrients and microcurrent
electricity showed slowing or reversing of the progress of
AMD for most subjects [18].
The microcurrent in this study was self-administered by
the patient, 2 treatments each day, using an automated
microcurrent stimulator with a preset current of 800
micro-amps at frequency settings of 292 Hz (6 minutes),
30 Hz (3 minutes), 9.1 Hz (2 minutes), and 0.3 Hz (1
minute) for a total of 12 minutes. The sham device was
identical to the treatment device, including LED indica-
tors and audible tones; however, there was no electrical
current output. Electrical current administered at levels
below 1 milliamp (1,000 micro-amps) has no detectable
sensation.
MCS treatment was found to have little significant effect
on any of the efficacy endpoints and thus was abandoned.
Only the nutritional supplement aspect of the study is
reported and discussed here (ie, patients receiving sham
MCS and nutritional supplement, n = 37).
Each subject was scheduled for 5 visits (Figure 1). During
the first visit, subjects who met the inclusion and exclu-
sion criteria (Table 1) and signed a consent to participate
underwent a comprehensive eye examination including
medical and ophthalmic history, refraction, BCVA meas-
ured by ETDRS (logMAR) at 4 m, biomicroscopy, intraoc-
ular lens evaluation, intraocular pressure, dilated fundus
exam, fluorescein angiogram and retinal photographs,
contrast sensitivity, full threshold visual fields, and macu-
lar testing (central 10° threshold visual filed). Addition-
ally, each subject completed the Visual Function
Questionanaire-25 (VFQ-25).
During the second visit at week 1, BCVA (logMAR) and
contrast sensitivity were measured and the nutritional
supplement was dispensed. The TOZAL nutritional sup-
plement formulation used in this study is outlined in
Table 2. This is a novel supplement formulation and is
currently patent pending. Subjects were instructed to self-
administer the oral supplements at 2 capsules 3 times per
day concurrent with food intake. Treatment compliance
was assessed at each subsequent visit via a daily patient
log.
During the third visit at week 2, BCVA (logMAR) and con-
trast sensitivity were measured.
During the fourth visit at week 11, BCVA (logMAR) and
contrast sensitivity were measured. In addition, retinal
photographs, fluorescein angiogram, macular testing, and
full threshold visual fields were conducted.
The final and exit visit was at week 24 and was a repeat of
the first visit in addition to a compliance assessment.BMC Ophthalmology 2007, 7:3 http://www.biomedcentral.com/1471-2415/7/3
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Study design Figure 1
Study design.
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Objective Measures
The primary objective was to measure the change in BCVA
from baseline to 6 months in subjects with non-exudative
macular degeneration treated with a nutritional supple-
ment. The secondary efficacy variable was objective signs
of improved macular function.
The primary safety variables were unexpected ocular or
systemic findings, adverse event rate, and temporary and
permanent discontinuation. Investigators were required
to report any treatment-related adverse events or serious
non-treatment-related adverse events and severe adverse
events requiring hospitalization.
Table 2: Nutritional supplement formulation
Component Weight Percent of daily value
Vitamin A (total) 28,640 IU 573%
Vitamin A 10,000 IU
Natural Beta-Carotene 18,640 IU
Vitamin C 452 mg 753%
Vitamin E 200 IU 667%
Zinc Oxide 69.6 mg 464%
Copper 1.6 mg 80%
Taurine 400 mg
EPA Omega-3 Fatty Acids 180 mg
DHA Omega-3 Fatty Acids 120 mg
Lutein (free, not esterified) 8 mg
Zeaxanthin 400 mcg
Table 1: Inclusion and exclusion criteria
Inclusion Criteria
• Signed written consent
• Between the ages of 50 and 90, inclusive
• Any race or gender
• Diagnosis of nonexudative (dry) AMD in at least 1 eye having > 10 large soft drusen 63 μm in diameter, within 3,000 um of the fovea center, 
documented on macular exam, retinal angiography and fundus photographs
• Able to understand and comply with the requirements of the trial
• BCVA in the trial eye(s) of 20/32 to 20/125 inclusive as measured by ETDRS (logMAR)
• Subjects must not have conditions that limit the view to the fundus (eg vitreous hemorrhage, cataracts, an epiretinal membrane). All subjects with 
= 2+ nuclear opacities and/or significant central opacity (PSC or ASC) > 1+ will undergo Potential Acuity Meter (PAM) testing. If the vision is = 2 
lines improved on PAM over standard acuity measurement then the subject will not be eligible for the trial
• Subjects must be available for a minimum trial duration of approximately 6 months
• Subjects must agree to take only the nutritional supplement that is provided during this study
• Subjects or eyes must not meet any of the exclusion criteria
Exclusion Criteria
Any of the following excluded a subject from the trial:
• Currently enrolled in an ophthalmic clinical trial
• Eyes with concomitant macular or choroidal disorders other than AMD and with indefinite signs of AMD
• Eyes with a diagnosis of exudative (wet) AMD with active subretinal neovascularization (SRNV) or CNV lesions requiring laser photocoagulation 
in the study eye
• Subjects with significant ocular lens opacities causing vision decrease
• Subjects with amblyopia
• Subjects with optic nerve disease (neuropathy, atrophy, papilledema), unstable glaucoma as defined by intraocular pressures greater than 25 mm 
Hg, 3 or more glaucoma medications, C/D of 0.8 or greater and visual fields consistent with glaucoma; history of retina-vitreous surgery, 
degenerative myopia, active posterior intraocular inflammatory disease, chronic use of topical ocular steroid medications, vasoproliferative 
retinopathies (other than AMD), rhegmatogenous retinal detachment, and inherited macular dystrophies
• Subjects with demand type pacemakers or epilepsy
• Subjects with uncontrolled hypertension (defined as diastolic of 90 or greater and systolic of 150 or greater)
• Subjects with recent history (within the previous year) of cerebral vascular disease
• manifested with transient ischemic attacks (TIA's) or cerebral vascular accidents (CVA's)
• Subjects with a history of AIDS
• Subjects who have received any previous experimental procedure in either eye or the use of any investigational drug or treatment within 30 days 
prior to enrolling in the trial
• Subjects who have had intraocular surgery in trial eye within 3 months prior to enrolling in the trial
• Smokers or any tobacco useBMC Ophthalmology 2007, 7:3 http://www.biomedcentral.com/1471-2415/7/3
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Adverse events included any undesirable clinical occur-
rence in a subject whether considered related to treatment
or not. Serious adverse events included those in which
information suggested that treatment caused or may have
caused or contributed to death or serious injury including,
but not limited to, permanent decrease in BCVA (≥ 2
lines) or hospitalization. Significant adverse events
included those that required medical intervention or war-
ranted discontinuation (temporary or permanent) from
the clinical trial. These events were non-sight-threatening
conditions that were determined to be device-related.
Non-significant adverse events were events that did not
warrant discontinuation from the clinical trial.
Subjects could discontinue or withdraw from the trial for
any reason. Investigators could discontinue a subject if, in
his/her opinion, it was in the best interest of the patient,
if there was non-compliance with study visits, if there was
more that 25% non-compliance with self-administration
of treatment, or if there was protocol deviation.
Placebo Arm
The IRB for this study determined that standard of care for
age-related macular degeneration must include an Age-
Related Eye Disease Study (AREDS)-type nutritional sup-
plement and that no true placebo arm would be permissi-
ble. A placebo arm was constructed from a review of the
literature. The exclusion and inclusion criteria used for the
Multicenter Investigation of Rheopheresis for AMD
(MIRA-1) trial were followed for the TOZAL study. Patient
demographics between subjects enrolled in the MIRA-1
study and the TOZAL study were similar. All subjects in
the MIRA-1 study received an oral supplement consisting
of 400 mg vitamin C, 200 IU vitamin E, 40 mg zinc, and
3,000 IU beta-carotene [7]. The results from the placebo
arm of the MIRA-1 study are used as a comparator in this
report.
Statistical Analysis
Sample size and power calculations were based on the pri-
mary efficacy endpoint. Results from two rheopheresis
studies (Brunner and MIRA-1) were used to estimate the
mean change expected [7,19]. Thirty-four patients were
included in the per-protocol analysis.
Statistical analyses were performed using SPSS for Win-
dows (SPSS 14.0, SPSS Inc., Chicago, IL). A paired t-test
was used to test the null hypothesis, with the average VA
score the same at baseline and follow-up. A two-sided
alpha level of 0.05 was used to determine statistical signif-
icance.
Primary efficacy endpoint analysis consisted of all rand-
omized and dispensed subjects with baseline and at least
1 post-treatment VA recorded. Baseline was equated to VA
measured as visit 2 (week 1). Change from baseline was
evaluated at weeks 11 and 24. Repeated measures mixed
model (Proc Mixed, SAS, 8.2) was fitted to compare mean
change in VA from baseline between the groups, with Visit
and Treatment-by-Visit interaction included as main
effects, baseline VA as covariate, and Eye as the within-
patient random effect.
A secondary analysis set was also constructed, comprised
of 1 eye per patient meeting the 20/32–20/125 entrance
VA criteria. If both the left and the right eye met the crite-
ria, the "best" eye was used.
The safety analysis set consisted of all randomized sub-
jects who received at least 1 dose of treatment. Incidence
of unexpected ocular or systemic findings, adverse events,
and temporary/permanent discontinuation were tabu-
lated and evaluated using Fisher's exact test. All tests were
carried out at α = 0.05, 2-sided.
Results
Demographics and Baseline Characteristics
Demographics and baseline characteristics of the 37
patients receiving the nutritional supplement are outlined
in Table 3. Subjects enrolled in the TOZAL study were
matched for inclusion and exclusion criteria with the
MIRA-1 study. Subjects in both cohorts were similar
across age, gender, ethnicity, and mean baseline BCVA [7].
Visual Acuity Outcomes
In the per-protocol analysis, the mean change from base-
line in ETDRS BCVA (logMAR) was calculated at 3 and 6
months (Figure 2). While the placebo arm experienced a
negative mean ETDRS line change of 1.49 lines at 6
months (loss of VA), the treatment group demonstrated a
positive mean ETDRS line change of 0.54 lines at 6
months (gain in VA). The mean logMAR line difference
between the treatment and placebo-control groups was
2.03 lines at 6 months postbaseline. A continual improve-
ment in BCVA (logMAR) over time was demonstrated in
the treatment group, while overall, the placebo arm con-
tinued to lose VA over time.
At 6 months, of those subjects in the treatment arm,
56.7% experienced improved BCVA (logMAR), 20.0%
maintained their BCVA (logMAR), and 23.3% experi-
enced worsened BCVA (logMAR). Overall 76.7% of
patients improved or maintained their BCVA (logMAR)
with the TOZAL nutritional supplementation (Figure 3).
Secondary Outcomes
Fluorescein angiogram, retinal photographs, contrast sen-
sitivity, full-threshold visual fields, macular testing (cen-
tral 10° threshold visual field), and the Visual FunctionBMC Ophthalmology 2007, 7:3 http://www.biomedcentral.com/1471-2415/7/3
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Questionanaire-25 (VFQ-25) were found to have little sig-
nificant change at 6 months.
Statistical Analyses
The average (SD) VA score was 0.409 (0.196) versus 0.355
(0.184) for baseline and follow-up respectively, t = -2.09;
df = 33; P = .045. Figure 4 demonstrates the average (and
95% confidence interval [CI] for the average) VA score at
baseline and at follow-up. Tables 4 and 5 show a statisti-
cally significant increase in the VA score from baseline to
follow-up. Thus, the null hypothesis, the average VA score
is the same at baseline and follow-up, was rejected and it
was concluded that there was a statistically significant
improvement in VA from baseline to follow-up. Table 5
shows that the average increase in VA was 0.0541 and the
95% CI for the average increase was (-0.107, -0.0013).
A post-hoc power analysis reveals that a sample size of 34
achieves 80% power to detect a difference of 0.062
between the baseline and follow-up average acuity score
assuming a standard deviation of the differences (follow-
up minus baseline) of 0.126 and with a significance level
(alpha) of 0.05 using a two-sided paired t-test. If the true
population change (follow-up minus baseline) was -
0.062 with a standard deviation of 0.126, then this study
would have had an 80% chance of detecting this differ-
ence at the 0.05 level of significance.
Adverse Effects
There were no significant systemic or ocular adverse
events related to the nutritional supplement. The most fre-
quent events were systemic gastrointestinal (GI) reactions,
including gastric upset, reflux, nausea, and taste perver-
sion. The majority of these events occurred in patients
who had not followed the prescribed procedure of taking
the supplement concurrent food intake. After adjusting
their treatment schedule to always administering the
nutritional supplement with food, the majority of GI
issues resolved. Overall, there does not appear to be any
significant adverse events related to the nutritional sup-
plement.
Discussion
Visual Acuity
Left untreated, patients with AMD are at risk for substan-
tial vision loss. The literature suggests that without inter-
vention, patients with AMD will experience a loss in VA of
at least 0.8 lines and up to 1.5 lines at 6 months [5-7].
The LAST study reported Snellen equivalent VA improve-
ments in both intervention groups (Group 1 L: lutein 10
mg; Group 2 L/A: lutein 10 mg/antioxidant/vitamin and
mineral broad-spectrum supplementation formula), with
mean eye improvements of 5.4 letters for group 1 L (95%
CI, 2.7–8.0, P = .01) and 3.5 letters for group 2 L/A (95%
CI, 0.8–6.1, P = .04) [13].
The 6-month LUXEA study demonstrated that supple-
mentation with carotenoids, lutein, and zeaxanthin can
improve mesoptic contrast acuity thresholds and visual
performance at low illumination [20].
Table 3: Demographics and baseline characteristics
Variable Parameter Treatment Group (n = 37) Placebo Group (n = 15)
Gender, n (%) Female 20 (54.1) 10 (67.0)
Male 17 (45.9) 5 (33.0)
Age Mean ± SD 76.3 ± 7.8 74.7 ± 5.9
Range 54 to 90 66 to 85
Ethnicity, n (%) African American 1 (2.7) 0 (0)
Asian 1 (2.7) 0 (0)
Caucasian 34 (91.9) 15 (100)
Hispanic 1 (2.7) 0 (0)
Current smoker, n (%) No 37 (100) -
Former smoker, n (%) No 25 (67.6) -
Yes 11 (29.7) -
Yes, 27 years ago 1 (2.7) -
Family history of MD, n (%) Yes 9 (24.3) -
Diabetes Yes 4 (10.8) -
Hypertension Yes 16 (43.2) -
Heart Disease Yes 13 (35.1) -
Other Yes 31 (83.8) -
Cataract surgery Yes 31 (83.8) -
Refractive surgery Yes 0 (0) -
Glaucoma Yes 8 (10.8) -
Diabetic retinopathy Yes 0 (0) -
Mean baseline BCVA (logMAR) Mean ± SD 0.41 ± 0.17 0.39 ± 0.17BMC Ophthalmology 2007, 7:3 http://www.biomedcentral.com/1471-2415/7/3
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The CARMIS study treated 153 patients with AMD
(AREDS category 3, 4) and VA of greater than 20/32 (0.3
LogMAR) with lutein 10 mg, zeaxanthin 1 mg, astaxan-
thin 4 mg, vitamin C 180 mg, vitamin E 30 mg, zinc 22.5
mg, and copper 1 mg (AZYR SIF®, Sifi Italy). Patients
received baseline, 6-month, and 1-year follow-up with
ETDRS and the 39-item NEI-VFQ. After 1 year, treated
patients showed stabilization of VA and significantly bet-
ter ETDRS scores (87 +/- 6) compared to controls (80 +/-
7; P = .02). VFQ-39 scores were significantly increased in
the treatment group (P = .001) [21].
The AREDS formula does not address the vast majority of
patients who want to improve visual function while pre-
venting advanced AMD. The targeted nutritional supple-
ment prescribed in the TOZAL trial allowed for 76.7% of
subjects to improve or maintain their VA, with up to 0.5
lines of VA improvement at 6 months.
Nutritional Supplements
Countless studies support the use of high-dose vitamins,
antioxidants, omega-3 fatty acids, zinc, and carotenoids in
the treatment of AMD. In addition, studies on the serum
levels of compounds including vitamins A, C, and E, car-
otenoids, zinc, selenium, and fibroblast growth factor in
subjects with AMD suggest that low levels of these com-
pounds put patients at greater risk for the development of
AMD [8-13]. However, recent reports of adverse events
associated with specific supplement components empha-
size the need for improved supplement formulation.
Mean ETDRS line change at 3 and 6 months Figure 2
Mean ETDRS line change at 3 and 6 months.
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Results of several large studies suggest that supplemental
beta-carotene increases the risk of developing lung cancer
in heavy smokers [22-24]. Thus, it has been recom-
mended that subjects with a history of smoking avoid sup-
plemental beta-carotene as part of an AMD prevention
program. However, an increased intake of foods rich in
beta-carotene has not been found to pose a heightened
risk for the development of lung cancer among current
and non-smokers [25]. Other carotenoids derived from
whole foods (lutein, zeaxanthin, and lycopene) are also
not associated with increased risk for lung cancer [25].
The supplement prescribed in the TOZAL study was
designed to address the risk of lung cancer among smok-
ers receiving supplemental beta-carotene by focusing on
beta-carotene derived from whole foods. The TOZAL sup-
plement contained 18,640 IU of natural beta-carotene
and 10,000 IU of vitamin A.
Recent data link high doses of vitamin E to a 13% increase
in the risk for heart failure [26]. In addition, a separate
study found that doses of 400 IU or more of vitamin E
increased the chance of early death or, according to the
[23,24] authors, "all-cause mortality" and should be
avoided [27]. In an attempt to address these potential risk
factors, the TOZAL supplement was designed with 200 IU
vitamin E.
Supplemental zinc has been found to decrease the rate of
loss of VA associated with AMD [16]. High doses of zinc
were included in the AREDS supplement (80 mg as zinc
oxide), as well as copper (2 mg) to help prevent copper
deficiency associated with zinc supplementation. In the
AREDS study, 7.5% of participants receiving a zinc-con-
taining nutritional supplements vs 5.0% of participants
receiving no zinc in their nutritional supplement reported
urinary tract problems that required hospitalization, as
well as increased rates of anemia (anemia results were
found not to be statistically significant) [16]. In an effort
to limit the adverse effects associated with high-dose zinc,
the TOZAL supplement was designed with 69.6 mg zinc
and 1.6 mg copper. No urinary tract adverse events or ane-
mia were reported during the TOZAL trial.
Table 4: Paired samples statistics
Mean N Std. Deviation Std. Error Mean
Pair 1 Baseline .409 34 .1963 .0337
Follow Up – 6 months .3553 34 .18384 .03153
Percent of subjects with improved or maintained BCVA at 6  months Figure 3
Percent of subjects with improved or maintained BCVA at 6 
months.
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In 1998, van den Berg et al found that lutein negatively
affected beta-carotene absorption when the two were
given simultaneously [28]. This decrease in absorption
may affect the amount of beta-carotene available for con-
version to retinol. In the AREDS study, lutein was not a
constituent of the formula, thereby circumventing the
issue. As newer formulas are developed that contain
lutein, consideration must be given to administering vita-
min A in addition to beta-carotene. In the TOZAL study,
this adjustment was made by administering 18,640 IU of
natural beta-carotene and 10,000 IU of vitamin A.
While toxicity has occurred at dosages of vitamin A of up
to 50,000 IU/day for a period of 18 to 24 months, [29-32]
an intake of 10,000 IU/day has not been associated with
toxicity and is considered safe.
Conclusion
The present study confirms previously published reports
on the direction and magnitude of improved visual acuity
in dry AMD [13,20,21]. That we did not find improve-
ments in other visual function parameters such as the con-
trast sensitivity function, is likely related to the short
duration of this study. The National Eye Institute's AREDS
II trial will follow a qualitatively similar supplement (i.e.,
the AREDS II formula has lower zinc, higher omega-3,
lutein and zeaxanthin in some of its treatment arms) as
TOZAL (without the addition of taurine). The results of
the TOZAL study reported here support the potential for
positive visual outcomes in the AREDS II trial.
We can not completely dismiss microcurrent stimulation
(with or without supplementation) as we did not evaluate
all available methods of stimulation.
Treatment based on dietary manipulation should con-
tinue to be pursued and refined as a simple, low-cost,
effective therapy for AMD.
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